2020
Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)
Gómez MA, Navas A, Prieto M, Giraldo-Parra L, Cossio A, Alexander N, Saravia N. Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia). Clinical Infectious Diseases 2020, 72: e484-e492. PMID: 32818964, PMCID: PMC8130027, DOI: 10.1093/cid/ciaa1206.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsMeglumine antimoniateCutaneous leishmaniasisBlood mononuclear cellsHuman cutaneous leishmaniasisIntracellular drug concentrationImmune gene expressionPK evidenceClinical cureParasite clearanceClinical resolutionDrug regimensMononuclear cellsPharmacodynamic parametersPharmacodynamic relationshipsLeishmania VianniaDrug treatmentTargeted immunomodulationTherapeutic outcomesImmune dynamicsDrug efficacyGene signatureDrug concentrationsProfile of expressionMicrobial kill
2007
Inferring activity changes of transcription factors by binding association with sorted expression profiles
Cheng C, Yan X, Sun F, Li LM. Inferring activity changes of transcription factors by binding association with sorted expression profiles. BMC Bioinformatics 2007, 8: 452. PMID: 18021409, PMCID: PMC2194743, DOI: 10.1186/1471-2105-8-452.Peer-Reviewed Original ResearchConceptsTranscription factorsExpression profilesMicroarray dataTarget gene selectionPost-transcriptional modificationsChIP-chip dataMicroarray expression profilesExpression differentiationLow expression levelsProfile of expressionTarget genesRegulatory mechanismsGene expressionBiological processesMicroarray studiesAffinity dataGene selectionSame machineryExpression levelsGenesActivity changesSignificance cutoffDifferentiationMeaningful hypothesesAffinity scores
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply